A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not adequately controlled by Somatostatin Analog (SSA) Therapy

Trial Profile

A Phase 3, Randomized, Placebo-controlled, Parallel-Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients with Carcinoid Syndrome not adequately controlled by Somatostatin Analog (SSA) Therapy

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2018

At a glance

  • Drugs Telotristat etiprate (Primary)
  • Indications Malignant carcinoid syndrome
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TELESTAR
  • Sponsors Lexicon Pharmaceuticals
  • Most Recent Events

    • 04 May 2018 According to a Lexicon Pharmaceuticals media,data from this trial were published in Clinical Therapeutics
    • 04 May 2018 Results published in the Lexicon Media Release
    • 28 Feb 2018 According to a Lexicon Pharmaceuticals media release, data from the study will be presented at the upcoming 15th Annual European Neuroendocrine Tumor Society Conference
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top